Monitoring safety of liposomes containing rifampicin on respiratory cell lines and in vitro efficacy against Mycobacterium bovis in alveolar macrophages

@article{Changsan2009MonitoringSO,
  title={Monitoring safety of liposomes containing rifampicin on respiratory cell lines and in vitro efficacy against Mycobacterium bovis in alveolar macrophages},
  author={N. Changsan and A. Nilkaeo and Pethchawan Pungrassami and T. Srichana},
  journal={Journal of Drug Targeting},
  year={2009},
  volume={17},
  pages={751 - 762}
}
Rifampicin-encapsulated liposome suspensions were prepared by a chloroform-film method and converted to dry powders by freeze-drying with mannitol as a cryoprotectant. The liposome suspension had multilamellar nanovesicles with 50% rifampicin encapsulation. The liposome dry powder comprised particles with a mass median aerodynamic diameter of 3.4 μm, with 60% present as a fine particle fraction. Rifampicin-encapsulated liposomes were evidently nontoxic to respiratory associated cells, including… Expand
Efficacy of Combined Rifampicin Formulations Delivered by the Pulmonary Route to Treat Tuberculosis in the Guinea Pig Model
Liposomes, as vehicles alone or in combination with rifampicin (RIF) microparticles (RMs), were evaluated as vehicles to enhance the permeation of RIF into granulomas. RIF liposomes (RLs) wereExpand
The Increase of Anti-tuberculosis Efficacy of Rifampicin Incorporated Into Phospholipid Nanoparticles with Sodium Oleate
Abstract —A drug formulation of the anti-tuberculosis drug rifampicin, incorporated in nanoparticles (of 20–30 nm in diameter) from soy phosphatidylcholine with the addition of sodium oleate, hasExpand
Inhaled pyrazinamide proliposome for targeting alveolar macrophages
TLDR
PZA-proliposomes were less toxic to respiratory-associated cells, and did not activate AMs to produce inflammatory mediators, including interleukin-1β, tumor necrosis factor-α, and nitric oxide, at a toxic level, suggesting that PZA- Proliposome are potential candidates for pulmonary tuberculosis treatment. Expand
Inhaled microparticles of antitubercular antibiotic for in vitro and in vivo alveolar macrophage targeting and activation of phagocytosis
TLDR
The administration of IM and INH-PM as dry powder inhalation formulation may reduce the treatment time of TB and chances of drug-resistant TB. Expand
The safety of ethambutol dihydrochloride dry powder formulations containing chitosan for the possibility of treating lung tuberculosis
TLDR
In vitro studies of a dry powder formulation of ethambutol dihydrochloride (EDH) showed a lower toxicity, higher potency and better permeation than the pure EDH, which could help to minimize the duration of treatment and the risk of developing multidrug resistance tuberculosis compared to the non-formulated EDH. Expand
Nano- and micro-based inhaled drug delivery systems for targeting alveolar macrophages
TLDR
The literature review shows that regulation of physicochemical parameters of particles could be a recipe to enhance macrophage targeting and uptake, and there is still a need to identify more target-specific receptors in order to facilitate drug targeting. Expand
Molecular implications in the nanoencapsulation of the anti-tuberculosis drug rifampicin within flower-like polymeric micelles.
TLDR
The present work explored the molecular implications governing the encapsulation and water solubilization of RIF within flower-like micelles of poly(epsilon-caprolactone)-b-poly(ethylene glycol)-poly(epilactone) (PCL-PEG-PCL) block copolymers to attain stable micellar systems with cores that are large enough to host the bulky RIF molecule. Expand
Effects of the encapsulation of usnic acid into liposomes and interactions with antituberculous agents against multidrug-resistant tuberculosis clinical isolates
TLDR
The in vitro antimycobacterial activity of UA-loaded liposomes (UA-Lipo) against MDR-TB was assessed by the microdilution method and the in vitro interaction of UA with antituberculous agents was carried out using checkerboard method. Expand
Exploring the Use of Lipid Based Nano-Formulations for the Management of Tuberculosis
TLDR
Lipid based nano-formulations are introduced as an alternative to the polymic formulations in the management of TB with an intention to overcome side effects related to drugs along with limitations of polymeric formulations. Expand
Nanoparticles as drug delivery system for antituberculous drugs
The increase of tuberculosis incidence in last decade stimulated elaboration of both new antituberculous drugs and also searches of optimizing delivery systems for existing drugs. It is determined byExpand
...
1
2
3
4
...

References

SHOWING 1-10 OF 43 REFERENCES
Design of liposomal aerosols for improved delivery of rifampicin to alveolar macrophages.
TLDR
The results suggest that the ligand-anchored liposomal aerosols are not only effective in rapid attainment of high-drug concentration in lung with high population of alveolar macrophages but also maintain the same over prolonged period of time. Expand
Physicochemical characterization and stability of rifampicin liposome dry powder formulations for inhalation.
TLDR
RIF in dry powder formulations was considerably more stable when compared to RIF aqueous solutions and RIF liposomal suspensions, and the SS-NMR results indicated that RIF was located between the acyl chains of the phospholipid bilayer and associated with CH molecules. Expand
Use of Microsphere Technology for Targeted Delivery of Rifampin to Mycobacterium tuberculosis-Infected Macrophages
TLDR
It is demonstrated that rifampin-loaded microspheres can be formulated for effective sustained and targeted delivery to host macrophages and were more effective at reducing M. tuberculosis intracellular growth than equivalent doses of rifampsin given as a free drug. Expand
Therapeutic efficacies of isoniazid and rifampin encapsulated in lung-specific stealth liposomes against Mycobacterium tuberculosis infection induced in mice
TLDR
Liposomal drugs at and below therapeutic concentrations were more effective than free drugs against tuberculosis, as evaluated on the basis of CFUs detected, organomegaly, and histopathology. Expand
Inhalable Microparticles Containing Drug Combinations to Target Alveolar Macrophages for Treatment of Pulmonary Tuberculosis
TLDR
Inhalable microparticles containing multiple anti-TB drugs offer promises of dose and dosing-frequency reduction, toxicity alleviation, and targeting Mφ-resident persistent mycobacteria. Expand
In vitro activities of free and liposomal drugs against Mycobacterium avium-M. intracellulare complex and M. tuberculosis.
TLDR
Results show that the antibacterial activities of certain drugs, particularly those of clofazimine and resorcinomycin, were maintained after the drugs were incorporated into liposomes, which had equivalent growth-inhibitory and killing effects on strains of M. avium, M. intracellulare, and Mycobacterium tuberculosis. Expand
Pulmonary delivery of liposomes
TLDR
It is concluded that liposome aerosols may play an important future role in the therapy of pulmonary diseases including intracellular infections, immunologie disorders, and gene defects. Expand
Interleukin-2 liposomes for primary immune deficiency using the aerosol route.
This is the first report of aerosol interleukin 2 (IL-2) liposome administration to individuals with immune deficiency. Parenteral IL-2 therapy has shown beneficial effects in some patients withExpand
Alveolar macrophage cell line is not activated by exposure to polymeric microspheres
Abstract An in vitro cell culture model based on a rat alveolar macrophage (AM) cell line, NR8383, was used to determine if poly( l -lactide) (PLA) microspheres prepared by the precipitation with aExpand
Liposomes for drug delivery to the lungs by nebulization.
TLDR
Results of NE% and NER% for Rif-loaded liposomes show that DSPC/Chol (2:1) is the best composition for RIF delivery in vesicular form to lungs, by nebulization, however if mucoadhesion is required, improvement may be needed. Expand
...
1
2
3
4
5
...